As we head into the fresh week of trading, note the action on Friday in shares of Predictive Technology Group Inc (OTCMKTS:PRED). The rally looks to be related to news of an uplist onto the OTCQX tier of the OTC market. But we would also point out the company’s announcement that a team mostly from PRED (including Kenneth Ward, M.D., laboratory director of Predictive Laboratories and chief executive officer of Juneau Biosciences; Rakesh Chettier M.S., director of biostatistics of Predictive Laboratories; and Hans Albertsen, Ph.D., chief scientific officer of Juneau Biosciences) has received the 2019 Endometriosis Special Interest Group (EndoSIG) Prize Paper in the “Best in Clinical/Population Science” category.
According to the release, Dr. Albertsen’s presentation entitled “Cytoskeletal and extracellular matrix genes are key contributors in the pathogenesis of endometriosis” was delivered at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress & Expo in Philadelphia on October 16. EndoSIG is a member group of ASRM aimed at fostering increased interest in the biology, pathophysiology and clinical management of endometriosis.
Predictive Technology Group Inc (OTCMKTS:PRED) promulgates itself as a company that, together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic and pharmaceutical therapeutic/human cells, tissues, and human cellular and tissue-based products (HCT/Ps).
The company operates through two segments, Regenerative Medicine Products and HCT/Ps, and Diagnostics and Therapeutics. It offers ARTguide, a genetic diagnostic and prognostic test for women experiencing infertility as a result of endometriosis and other health concerns; and regenerative medicine products, including AmnioCyteT, AmnioCyte PlusT, PolyCyteT, and CoreCyteT.
The company was formerly known as Global Enterprises Group, Inc. and changed its name to Predictive Technology Group, Inc. in July 2015. Predictive Technology Group, Inc. was founded in 2005 and is headquartered in Salt Lake City, Utah.
According to company materials, “Predictive Technology Group aims to revolutionize patient care through predictive data analytics, novel gene-based diagnostics and companion therapeutics through its subsidiaries Predictive Therapeutics, Predictive Biotech, and Predictive Laboratories. These subsidiaries are focused on endometriosis, scoliosis, degenerative disc disease and human cell and tissue products. The subsidiaries use genetic and other information as cornerstones in the development of new diagnostics that assess a person’s risk of illness and therapeutic products designed to identify, prevent and treat diseases more effectively.”
Find out when $PRED reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, PRED just announced that a team mostly from the company has received the 2019 Endometriosis Special Interest Group (EndoSIG) Prize Paper in the “Best in Clinical/Population Science” category.
We’ve witnessed 28% tacked on to share pricing for the name in the past week. In addition, the stock has witnessed a pop in interest, as transaction volume levels have recently pushed topping 120% over what the stock has registered over the longer term.
“We are honored to receive this prestigious award from the ASRM Research Committee,” said Dr. Albertsen. “As endometriosis is generally characterized as a hormonal and inflammatory disease, current therapies often come with significant debilitating side effects. The scientific breakthroughs reported in these award-winning discoveries provide Predictive with insights into new non-hormonal therapies.”
At this time, carrying a capital value in the market of $475M, PRED has a bankroll ($1.8M) of cash on the books, which is balanced by about $14.1M in total current liabilities. One should also note that debt has been growing over recent quarters. PRED is pulling in trailing 12-month revenues of $43.5M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 88%. You can bet we will update this one again as new information comes into view. Sign-up for continuing coverage on shares of $PRED stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $PRED, either long or short, and we have not been compensated for this article.